Ovarian Cancer

New treatment studied at MCG

Published in Women's Health Weekly, May 15th, 2003

An agent that stimulates the immune system to identify and eliminate abnormal cells may give women with the most common type of ovarian cancer new hope, says a Medical College of Georgia (MCG) gynecologic oncologist.

MCG is taking part in an international study that adds interferon gamma 1-b to the standard treatment protocol for women with late-stage ovarian cancer, said Dr. Sharad Ghamande, a principal investigator. Dr. Michael S. Macfee, chief of the MCG section of gynecologic oncology, is a sub-investigator on the study.

Experience with interferon gamma 1-b in laboratory studies and previous clinical trials indicates that the drug may...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry